Omeros (NASDAQ:OMER) Stock Crosses Above Two Hundred Day Moving Average – Here’s What Happened

Omeros Corporation (NASDAQ:OMER)’s share price crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $9.15 and traded as high as $11.71. Omeros shares last traded at $11.19, with a volume of 749,069 shares traded.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on OMER. Weiss Ratings restated a “sell (d-)” rating on shares of Omeros in a research note on Thursday, January 22nd. HC Wainwright upped their price objective on Omeros from $20.00 to $40.00 and gave the stock a “buy” rating in a report on Thursday, January 8th. Wall Street Zen cut Omeros from a “hold” rating to a “sell” rating in a research report on Saturday, January 10th. Finally, D. Boral Capital reissued a “buy” rating and issued a $36.00 target price on shares of Omeros in a report on Tuesday, January 27th. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Omeros presently has a consensus rating of “Moderate Buy” and a consensus target price of $40.33.

Omeros Price Performance

The business’s 50-day simple moving average is $11.98 and its two-hundred day simple moving average is $9.15. The stock has a market capitalization of $793.37 million, a price-to-earnings ratio of -5.54 and a beta of 2.45.

Insider Buying and Selling at Omeros

In other news, CAO David J. Borges sold 30,000 shares of the stock in a transaction dated Tuesday, January 13th. The stock was sold at an average price of $12.31, for a total value of $369,300.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 12.90% of the stock is owned by insiders.

Institutional Trading of Omeros

A number of hedge funds have recently made changes to their positions in OMER. Farther Finance Advisors LLC increased its position in shares of Omeros by 16.5% during the fourth quarter. Farther Finance Advisors LLC now owns 7,106 shares of the biopharmaceutical company’s stock worth $122,000 after acquiring an additional 1,004 shares during the last quarter. State of Wyoming purchased a new position in Omeros in the fourth quarter valued at about $25,000. AQR Capital Management LLC boosted its holdings in Omeros by 7.2% in the fourth quarter. AQR Capital Management LLC now owns 22,838 shares of the biopharmaceutical company’s stock valued at $392,000 after purchasing an additional 1,532 shares during the last quarter. ProShare Advisors LLC increased its holdings in Omeros by 12.1% during the 4th quarter. ProShare Advisors LLC now owns 15,171 shares of the biopharmaceutical company’s stock worth $261,000 after purchasing an additional 1,637 shares during the last quarter. Finally, Cerity Partners LLC raised its position in shares of Omeros by 6.1% in the 4th quarter. Cerity Partners LLC now owns 30,450 shares of the biopharmaceutical company’s stock valued at $523,000 after purchasing an additional 1,750 shares in the last quarter. Hedge funds and other institutional investors own 48.79% of the company’s stock.

Omeros Company Profile

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.